Region includes Southern California and Arizona Overview We are looking for an experienced Thought Leader Liaison to support the promotion of AMVUTTRA® (vutrisiran), an RNAi therapeutic that was approved in June 2022 by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and help support transitions from ONPATTRO® (patisiran) for appropriate patients. ONPATTRO is the first-ever RNAi therapeutic approved in August 2018 by the FDA in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In addition, this role will also have the opportunity to be a TLL responsible for the potential launch of patisiran in ATTR amyloidosis with cardiomyopathy. The supplemental NDA for patisiran has been submitted for review by the FDA. The Thought Leader Liaison (TLL) is a commercial, field-based, customer facing role primarily focused on the identification and development of enduring relationships with both current and emerging key opinion leaders (KOLs) within the US hATTR amyloidosis community. S/he will focus on engaging KOLs to solicit insights and develop advocacy aligned to commercial and marketing strategy and messaging for hATTR amyloidosis diagnosis and management and Alnylam’s approved therapies for hATTR amyloidosis. As integral strategic partners to Alnylam’s internal and field-based teams, TLLs support cross functional, commercial opportunities with KOLs including marketing education initiatives, advisory boards, speakers bureau strategy, congress strategy, and consulting opportunities. Additionally, the TLL helps to inform commercial and marketing strategy, messaging, and resources through the sharing of insights and connecting KOLs with Alnylam cross functional partners. The TLL role will work closely and collaboratively with internal partners including marketing, medical affairs, sales, legal, and compliance to maintain KOL coordination but also to manage appropriate distinction of roles and boundaries among the expertise areas. The TLL will be accountable for commercial KOL engagement in the West region and will report to the West Director, TLL Lead. Key Responsibilities · Creates and executes on objective-based, KOL engagement plans to include the identification and curation of relationships with current and emerging KOLs in the academic and community setting to support insight generation and development of advocacy in a dynamic market. · Solicits pre-determined disease and brand insights through field-based, 1v1 KOL interactions and utilizes these insights to identify market gaps and/or market opportunities to support the development of commercial and marketing strategy, initiatives, and resources. · Engages in field-based, 1v1 interactions with KOLs using approved TLL resources to generate insights and align KOL beliefs to hATTR amyloidosis and AMVUTTRA® (vutrisiran) disease and brand messaging to support advocacy development. · Identify KOLs for approved Alnylam consulting opportunities including the speaker’s bureau, congress and regional symposiums, advisory boards, review of marketing materials, and KOL videos, etc. · Support the execution of US marketing advisory boards including insights for creation of content and selection of advisors. · Owns, develops, and executes on KOL engagement strategies for Alnylam’s participation at key, national congresses within the hTTR amyloidosis community. · Develops opportunities to communicate execution and commercial impact of the TLL role with internal partners and maintains proactive communication plans with cross functional partners to coordinate activity and ensure role clarity. · Operates to the highest standard in alignment with Alnylam’s code of ethics and compliance SOPs, ensuring all interactions with KOLs are on-label and consistent with commercial, regulatory, and legal guidelines. Qualifications · BS/BA degree (science degree preferred) · 8+ years of experience in one or more of the following: Field Sales, Product Marketing, and / or Medical Affairs within the pharmaceutical or biotech industry · Experience and proven success in working with and interacting with HCPs (Healthcare Providers), KOLs (Key Opinion Leaders), and COEs (Centers of Excellence) · Experience in rare/orphan diseases desirable · A track record of executing strategic and tactical plans that have delivered strong commercial results. · Deep experience in Neurology and Cardiology is preferred. · Proven ability to influence without authority and work with cross-functional teams in the development and delivery of brand strategic imperatives. · Thrives in a highly entrepreneurial biotech environment and embraces Alnylam’s culture of science, passion, and urgency. · Maintains a growth mindset and uses curiosity to uncover opportunities for continuous development and improvement. · Excellent interpersonal and communication skills. · Valid driver’s license · Ability to travel 50-65% as necessary. Must live within specified territory Expectations: Act compliantly and with highest integrity. Clear Alignment with Alnylam Core Values: · Commitment to People · Innovation and Discovery · Sense of Urgency · Open Culture · Passion for Excellence About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.